☰

Yehenew M. Agazie - Publications

Affiliations: 
School of Medicine West Virginia University, Morgantown, WV, United States 
Area:
Biochemistry, Cell Biology, Oncology
Website:
https://directory.hsc.wvu.edu/Profile/28124
Tree Info Similar researchers PubMed Report error

33 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2023 Lade DM, Agazie YM. Targeting SHP2 with an Active Site Inhibitor Blocks Signaling and Breast Cancer Cell Phenotypes. Acs Bio & Med Chem Au. 3: 418-428. PMID 37876496 DOI: 10.1021/acsbiomedchemau.3c00024  0.556
2022 Lade DM, Nicoletti R, Mersch J, Agazie YM. Design and synthesis of improved active-site SHP2 inhibitors with anti-breast cancer cell effects. European Journal of Medicinal Chemistry. 247: 115017. PMID 36584630 DOI: 10.1016/j.ejmech.2022.115017  0.499
2021 Martin E, Agazie YM. SHP2 potentiates the oncogenic activity of beta-catenin to promote triple-negative breast cancer. Molecular Cancer Research : McR. PMID 34389690 DOI: 10.1158/1541-7786.MCR-21-0060  0.368
2020 Hartman Z, Geldenhuys WJ, Agazie YM. Novel Small-Molecule Inhibitor for the Oncogenic Tyrosine Phosphatase SHP2 with Anti-Breast Cancer Cell Effects. Acs Omega. 5: 25113-25124. PMID 33043190 DOI: 10.1021/acsomega.0c02746  0.788
2020 Hartman Z, Geldenhuys WJ, Agazie YM. A specific amino acid context in EGFR and HER2 phosphorylation sites enables selective binding to the active site of Src homology phosphatase 2 (SHP2). The Journal of Biological Chemistry. PMID 32024694 DOI: 10.1074/Jbc.Ra119.011422  0.762
2020 Agazie Y, Hartman Z. Abstract P3-10-20: Targeting the tyrosine phosphatase SHP2 is efficacious against HER2-positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P3-10-20  0.807
2019 Agazie Y, Hartman Z. Abstract P6-20-17: Targeting SHP2 for the treatment of HER2-positive breast cancer Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P6-20-17  0.787
2018 Zhao H, Martin E, Matalkah F, Shah N, Ivanov A, Ruppert JM, Lockman PR, Agazie YM. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis. Oncogene. PMID 30467378 DOI: 10.1038/S41388-018-0574-8  0.569
2016 Matalkah F, Martin E, Zhao H, Agazie YM. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer. Breast Cancer Research : Bcr. 18: 2. PMID 26728598 DOI: 10.1186/S13058-015-0659-Z  0.597
2015 Zhao H, Agazie YM. Inhibition of SHP2 in basal-like and triple-negative breast cells induces basal-to-luminal transition, hormone dependency, and sensitivity to anti-hormone treatment. Bmc Cancer. 15: 109. PMID 25885600 DOI: 10.1186/S12885-015-1131-2  0.591
2015 Farrugia MK, Sharma SB, Lin CC, McLaughlin SL, Vanderbilt DB, Ammer AG, Salkeni MA, Stoilov P, Agazie YM, Creighton CJ, Ruppert JM. Regulation of anti-apoptotic signaling by Kruppel-like factors 4 and 5 mediates lapatinib resistance in breast cancer. Cell Death & Disease. 6: e1699. PMID 25789974 DOI: 10.1038/cddis.2015.65  0.497
2014 Zhao H, Agazie YM. Abstract 2014: SHP2 stabilizes EGFR and beta-catenin to promote the transformation and tumorigenic potential of basal-like and triple-negative breast cancer cells Cancer Research. 74: 2014-2014. DOI: 10.1158/1538-7445.Am2014-2014  0.578
2013 Hartman ZR, Schaller MD, Agazie YM. The tyrosine phosphatase SHP2 regulates focal adhesion kinase to promote EGF-induced lamellipodia persistence and cell migration. Molecular Cancer Research : McR. 11: 651-64. PMID 23512980 DOI: 10.1158/1541-7786.Mcr-12-0578  0.784
2013 Matalka F, Zhao H, Agazie YM. Abstract LB-280: Inhibition of SHP2 in basal-like and triple-negative breast cancer cells induces basal-to-luminal transition, suppresses tumorigenesis, and blocks metastasis. Cancer Research. 73. DOI: 10.1158/1538-7445.Am2013-Lb-280  0.604
2012 Hartman Z, Zhao H, Agazie YM. HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling. Oncogene. 32: 4169-80. PMID 23027125 DOI: 10.1038/Onc.2012.418  0.783
2012 Zhou X, Agazie YM. The signaling and transformation potency of the overexpressed HER2 protein is dependent on the normally-expressed EGFR. Cellular Signalling. 24: 140-50. PMID 21911055 DOI: 10.1016/J.Cellsig.2011.08.015  0.557
2011 Matalka F, Hartman Z, Agazie YM. Abstract 238: Inhibition of SHP2 abolishes mammary tumorigenesis in mice Cancer Research. 71: 238-238. DOI: 10.1158/1538-7445.Am2011-238  0.797
2011 Matalka F, Agazie Y. Abstract B69: SHP2 as a novel therapeutic target for triple-negative breast cancer Cancer Epidemiology, Biomarkers & Prevention. 20. DOI: 10.1158/1055-9965.Disp-11-B69  0.655
2011 Agazie Y, Matalka F, Hartman Z. P3-01-15: The Role of Src Homology Phosphotyrosyl Phosphatase-2 in Basal-Type/Triple-Negative Breast Cancer – Implications for Targeted Therapy. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P3-01-15  0.814
2011 Hartman Z, Agazie Y. P2-02-05: Molecular Mechanism for Src Homology Phosphotyrosyl Phosphatase 2 Regulation of Cell Motility and Migration. Cancer Research. 71. DOI: 10.1158/0008-5472.Sabcs11-P2-02-05  0.804
2010 Zhou X, Ahmed N, Agazie YM. Abstract 3121: A novel molecular mechanism for HER2-induced sustained signaling and transformation Cancer Research. 70: 3121-3121. DOI: 10.1158/1538-7445.Am10-3121  0.555
2009 Zhou X, Agazie YM. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation. The Journal of Biological Chemistry. 284: 12226-34. PMID 19261604 DOI: 10.1074/Jbc.M900020200  0.57
2008 Zhou X, Coad J, Ducatman B, Agazie YM. SHP2 is up-regulated in breast cancer cells and in infiltrating ductal carcinoma of the breast, implying its involvement in breast oncogenesis. Histopathology. 53: 389-402. PMID 18643929 DOI: 10.1111/J.1365-2559.2008.03103.X  0.484
2008 Zhou XD, Agazie YM. Inhibition of SHP2 leads to mesenchymal to epithelial transition in breast cancer cells. Cell Death and Differentiation. 15: 988-96. PMID 18421299 DOI: 10.1038/cdd.2008.54  0.589
2006 Burks J, Agazie YM. Modulation of α-catenin Tyr phosphorylation by SHP2 positively effects cell transformation induced by the constitutively active FGFR3 Oncogene. 25: 7166-7179. PMID 16767162 DOI: 10.1038/Sj.Onc.1209728  0.485
2006 Merritt R, Hayman MJ, Agazie YM. Mutation of Thr466 in SHP2 abolishes its phosphatase activity, but provides a new substrate-trapping mutant. Biochimica Et Biophysica Acta. 1763: 45-56. PMID 16413071 DOI: 10.1016/J.Bbamcr.2005.11.013  0.373
2003 Agazie YM, Hayman MJ. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Molecular and Cellular Biology. 23: 7875-86. PMID 14560030 DOI: 10.1128/Mcb.23.21.7875-7886.2003  0.375
2003 Agazie YM, Movilla N, Ischenko I, Hayman MJ. The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3. Oncogene. 22: 6909-18. PMID 14534538 DOI: 10.1038/Sj.Onc.1206798  0.387
2003 Agazie YM, Hayman MJ. Development of an efficient "substrate-trapping" mutant of Src homology phosphotyrosine phosphatase 2 and identification of the epidermal growth factor receptor, Gab1, and three other proteins as target substrates. The Journal of Biological Chemistry. 278: 13952-8. PMID 12582165 DOI: 10.1074/Jbc.M210670200  0.35
2002 Agazie Y, Ischenko I, Hayman M. Concomitant activation of the PI3K-Akt and the Ras-ERK signaling pathways is essential for transformation by the V-SEA tyrosine kinase oncogene Oncogene. 21: 697-707. PMID 11850798 DOI: 10.1038/Sj.Onc.1205115  0.306
1998 Wilden PA, Agazie YM, Kaufman R, Halenda SP. ATP-stimulated smooth muscle cell proliferation requires independent ERK and PI3K signaling pathways. American Journal of Physiology. Heart and Circulatory Physiology. 275: H1209-H1215. PMID 29586809 DOI: 10.1152/ajpheart.1998.275.4.H1209  0.368
1996 Agazie YM, Burkholder GD, Lee JS. Triplex DNA in the nucleus: Direct binding of triplex-specific antibodies and their effect on transcription, replication and cell growth Biochemical Journal. 316: 461-466. PMID 8687388 DOI: 10.1042/Bj3160461  0.583
1995 Latimer LJ, Agazie YM, Braun RP, Hampel KJ, Lee JS. Specificity of monoclonal antibodies produced against phosphorothioate and ribo modified DNAs. Molecular Immunology. 32: 1057-64. PMID 8544855 DOI: 10.1016/0161-5890(95)00086-0  0.683
Show low-probability matches.